4:29 PM
 | 
Sep 11, 2017
 |  BC Extra  |  Clinical News

Incyte reports PFS data for IDO1 combo to treat melanoma

Incyte Corp. (NASDAQ:INCY) and Merck & Co. Inc. (NYSE:MRK) reported updated data from a cohort of advanced melanoma patients in the ongoing Phase I/II ECHO-202/KEYNOTE-037 study of epacadostat (INCB24360) in combination with PD-1 inhibitor Keytruda pembrolizumab. Epacadostat is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Data were presented at the European Society for Medical Oncology meeting...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >